Eli Lilly's stock declined 1.63% on December 1, 2025 to close at $1,057.89, with pre-market trading showing a further 0.15% dip to $1,056.26 on December 2. The decline reflects broader market headwinds including tech sector pressure (NVIDIA down 1.24%), crypto volatility (Bitcoin down 5.08%), and risk-off sentiment following the Bank of Japan's rate hike indication. Despite near-term weakness, analyst sentiment remains constructive with consensus "Strong Buy" ratings and price targets ranging from $925.50 to $1,300, suggesting 3.2% to 32.7% upside potential. The stock continues benefiting from strong GLP-1 prescription momentum for Mounjaro and Zepbound, with recent data showing 5% and 4% week-over-week increases respectively.